In vitro diagnostic is a non-invasive technique utilized in early diagnosis and management of diseases. The In vitro diagnostic offers detection of several diseases, and helps in management and maintenance of diseases related conditions. IVD are reagents, instruments, and systems intended to diagnose various diseases that include determination of the state of health, and also cure, mitigate, treat, or prevent diseases. The Europe IVD market accounted for $19,124 million in 2016, and is estimated to reach $26,623 million by 2023, growing at a CAGR of 4.7% during the analysis period of 2017–2023.... Research Beam Model: Research Beam Product ID: 2107716 5370 USD New
Europe IVD Market by Product Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Blood Testing, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Other Indications), and by End Users (Standalone Laboratory, Hospitals, Academic and Medical Schools, Point of Care Testing, and Others) - Opportunity Analysis and Industry Forecast, 2017-2023

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Europe IVD Market by Product Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Blood Testing, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Other Indications), and by End Users (Standalone Laboratory, Hospitals, Academic and Medical Schools, Point of Care Testing, and Others) - Opportunity Analysis and Industry Forecast, 2017-2023

 
  • Category : Healthcare
  • Published On : September  2017
  • Pages :
 
 

In vitro diagnostic is a non-invasive technique utilized in early diagnosis and management of diseases. The In vitro diagnostic offers detection of several diseases, and helps in management and maintenance of diseases related conditions. IVD are reagents, instruments, and systems intended to diagnose various diseases that include determination of the state of health, and also cure, mitigate, treat, or prevent diseases. The Europe IVD market accounted for $19,124 million in 2016, and is estimated to reach $26,623 million by 2023, growing at a CAGR of 4.7% during the analysis period of 2017–2023.

The growth of the IVD market in Europe is primarily characterized by the increase in geriatric & amputee population, high incidence of chronic diseases, and growth in investment on hospital infrastructure. Point-of-care testing is widely used in Europe due to the ease of use and convenience. Recently, European Union (EU) regulatory framework for IVD has introduced significant changes to the previous regulatory framework. This updated policy is expected to enable new product launches at a much faster rate as the new EU regulatory authority aims to provide a robust, transparent, and sustainable regulatory framework.

The market is segmented on the basis of product type, techniques, application, end user, and country. By product type, the market is categorized into reagents, instruments and software & services. On the basis of techniques, it is categorized into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. Application segment covered in the study includes infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end user, it is classified into hospitals, academic and medical schools, point-of-care testing, and others. By geography, it is analyzed across the UK, Germany, France, Spain, Italy, and Rest of Europe.

KEY BENEFITS FOR STAKEHOLDERS

  • Comprehensive analysis of factors that drive and restrict the growth of the Europe IVD market is provided.
  • The projections in the market are made by studying the current market trends and future market potential for the period in terms of value.
  • Extensive analysis by technology and application helps understand the various trends and prevailing opportunities in the respective market
  • Key market players within the Europe IVD market are profiled in the market and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the market.
  • Comprehensive analysis of all countries is provided that determines the prevailing opportunities in these countries.

KEY MARKET SEGMENTS

By Product Type

  • Reagents
  • Instruments
  • Software and Services

By Techniques

  • Immunodiagnostics
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Chemiluminescence Immunoassays (CLIAS)
    • Fluorescence Immunoassays (FIAS)
    • Colorimetric Immunoassays (CIS)
    • Rapid Tests
    • Enzyme-Linked Immunospot Assays (ELISPOT)
    • Radioimmunoassay
    • Western Blot
  • Blood Testing
  • Molecular Diagnostics
    • Polymerase Chain Reaction (PCR)
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Hybridization
    • DNA Diagnostics
    • Microarrays
    • Others
  • Tissue Diagnostics
  • Clinical Chemistry
    • Basic Metabolic Panel
    • Liver Panel
    • Lipid Profile
    • Thyroid Function Panel
    • Renal Profile
    • Electrolyte Panel
    • Specialty Chemicals
  • Other IVD Techniques

By Application

  • Infectious Diseases
  • Cancer
  • Cardiac Diseases
  • Immune System Disorders
  • Nephrological Diseases
  • Gastrointestinal Diseases
  • Other Indications

By End Users

  • Standalone Laboratory
  • Hospitals
  • Academic and Medical Schools
  • Point of Care Testing
  • Others

By Country

  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe

List of players profiled in the report

  • Thermo Fisher Scientific Inc.
  • Alere Inc.
  • Biomerieux
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Becton Dickinson and Company
  • Bio-Rad Laboratories
  • Bayer AG
  • Sysmex Corporation
  • Johnson & Johnson

CHAPTER 1 INTRODUCTION

1.1 REPORT DESCRIPTION
1.2 KEY BENEFITS
1.3 KEY MARKET SEGMENTS
1.4 RESEARCH METHODOLOGY

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1 MARKET DEFINITION AND SCOPE
3.2 KEY FINDINGS

3.2.1 Top investment pockets
3.2.2 Top winning strategies

3.3 PORTERS FIVE FORCES ANALYSIS

3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Threat of substitute
3.3.5 Competitive rivalry

3.4 MARKET SHARE ANALYSIS, 2016
3.5 MARKET DYNAMICS

3.5.1 Drivers

3.5.1.1 Increasing incidence of chronic and infectious diseases
3.5.1.2 Technological advancements in IVD
3.5.1.3 Emergence of minimal invasive technologies
3.5.1.4 Increasing government expenditures on healthcare
3.5.1.5 Increase in popularity of personalized medicine approach

3.5.2 Restraint

3.5.2.1 Unclear reimbursement policies
3.5.2.2 Stringent regulatory policies

3.5.3 Opportunity

3.5.3.1 Potential opportunities for outsourcing
3.5.3.2 Convergence of new technologies

CHAPTER 4 IVD MARKET, BY PRODUCT TYPE

4.1 OVERVIEW

4.1.1 Market size and forecast

4.2 REAGENTS

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 INSTRUMENTS

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.4 SOFTWARE AND SERVICES

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast

CHAPTER 5 IVD MARKET, BY TECHNIQUE

5.1 OVERVIEW

5.1.1 Market size and forecast

5.2 IMMUNODIAGNOSTICS

5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.2.4 Enzyme-linked immunosorbent assay (ELISA)

5.2.4.1 Market size and forecast
5.2.4.2 Chemiluminescence immunoassay (CLIA)

5.2.4.2.1 Market size and forecast

5.2.4.3 Fluorescence immunoassay (FIA)

5.2.4.3.1 Market size and forecast

5.2.4.4 Colorimetric immunoassay (CI)

5.2.4.4.1 Market size and forecast

5.2.5 Rapid tests

5.2.5.1 Market size and forecast

5.2.6 Enzyme-linked immunospot (ELISPOT)

5.2.6.1 Market size and forecast

5.2.7 Radioimmunoassay (RIA)

5.2.7.1 Market size and forecast

5.2.8 Western blot

5.2.8.1 Market size and forecast

5.3 BLOOD TESTING

5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast

5.4 MOLECULAR DIAGNOSTICS

5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.4.4 Polymerize chain reaction (PCR)

5.4.4.1 Market size and forecast

5.4.5 Isothermal nucleic acid technology (INAAT)

5.4.5.1 Market size and forecast

5.4.6 Hybridization

5.4.6.1 Market size and forecast

5.4.7 DNA diagnostics

5.4.7.1 Market size and forecast

5.4.8 Microarray

5.4.8.1 Market size and forecast

5.4.9 Others

5.4.9.1 Market size and forecast

5.5 TISSUE DIAGNOSTICS

5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast

5.6 CLINICAL CHEMISTRY

5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size and forecast
5.6.4 Basic metabolic panel

5.6.4.1 Market size and forecast

5.6.5 Liver panel

5.6.5.1 Market size and forecast

5.6.6 Renal profile

5.6.6.1 Market size and forecast

5.6.7 Lipid profile

5.6.7.1 Market size and forecast

5.6.8 Thyroid function panel

5.6.8.1 Market size and forecast

5.6.9 Electrolyte panel

5.6.9.1 Market size and forecast

5.6.10 Speciality chemicals

5.6.10.1 Market size and forecast

5.7 OTHER IVD TECHNIQUES

5.7.1 Key market trends
5.7.2 Key growth factors and opportunities
5.7.3 Market size and forecast

CHAPTER 6 IVD MARKET, BY APPLICATION

6.1 INFECTIOUS DISEASES

6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast

6.2 CANCER

6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast

6.3 CARDIAC DISEASES

6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast

6.4 IMMUNE SYSTEM DISORDERS

6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast

6.5 NEPHROLOGICAL DISEASES

6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast

6.6 GASTROINTESTINAL DISEASES

6.6.1 Key market trends
6.6.2 Key growth factors and opportunities
6.6.3 Market size and forecast

6.7 OTHERS INDICATIONS

6.7.1 Key market trends
6.7.2 Key growth factors and opportunities
6.7.3 Market size and forecast

CHAPTER 7 IVD MARKET BY END USERS

7.1 STANDALONE LABORATORIES

7.1.1 Market size and forecast

7.2 HOSPITALS

7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast

7.3 ACADEMIC AND MEDICAL SCHOOLS

7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast

7.4 POINT OF CARE TESTING

7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast

7.5 OTHERS END-USER

7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast

CHAPTER 8 EUROPE IVD MARKET BY COUNTRY

8.1 Key market trends
8.2 Key growth factors and opportunities
8.3 Market size and forecast
8.4 Germany

8.4.1 Market size and forecast

8.5 France

8.5.1 Market size and forecast

8.6 UK

8.4.6.1 Market size and forecast

8.7 Spain

8.7.1 Market size and forecast

8.8 Italy

8.8.1 Market size and forecast

8.9 Rest of Europe

8.9.1 Market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1 THERMO FISHER SCIENTIFIC INC.

9.1.1 Company overview
9.1.2 Business performance
9.1.3 Key strategies and development

9.2 ALERE INC.

9.2.1 Company overview
9.2.2 Business performance
9.2.3 Key strategies and developments

9.3 BIOMERIEUX

9.3.1 Company overview
9.3.2 Business performance
9.3.3 Key strategies and developments

9.4 DANAHER CORPORATION

9.4.1 Company overview
9.4.2 Business performance
9.4.3 Key strategies and development

9.5 F. HOFFMANN-LA ROCHE AG

9.5.1 Company overview
9.5.2 Business performance
9.5.3 Key strategies and developments

9.6 BECTON DICKINSON AND COMPANY

9.6.1 Company overview
9.6.2 Business performance
9.6.3 Key strategies and development

9.7 BIO-RAD LABORATORIES

9.7.1 Company overview
9.7.2 Business performance
9.7.3 Key strategies and developments

9.8 BAYER AG

9.8.1 Company overview
9.8.2 Business performance
9.8.3 Key strategies and development

9.9 SYSMEX CORPORATION

9.9.1 Company overview
9.9.2 Business performance
9.9.3 Key strategies and developments

9.10 JOHNSON & JOHNSON

9.10.1 Company overview
9.10.2 Business performance
9.10.3 Key strategies and development

List of Tables

TABLE 1 INCIDENCE OF DISEASES
TABLE 2 EUROPE IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 3 EUROPE IVD REAGENTS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 4 EUROPE IVD INSTRUMENTS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 5 EUROPE IVD SOFTWARE & SERVICES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 6 EUROPE IVD MARKET BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 7 EUROPE IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY TYPES, 2016-2023 ($MILLION)
TABLE 8 EUROPE IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY COUNTRY,2016-2023 ($MILLION)
TABLE 9 EUROPE IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET FOR ELISA, BY TYPES, 2016-2023 ($MILLION)
TABLE 10 EUROPE IVD BLOOD TESTING TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 11 EUROPE IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 12 EUROPE IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 13 EUROPE IVD TISSUE DIAGNOSTICS TECHNIQUE MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 14 EUROPE IVD CLINICAL CHEMISTRY TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 15 EUROPE OTHER IVD TECHNIQUES MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 16 EUROPE IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 17 EUROPE IVD INFECTIOUS DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 18 EUROPE IVD CANCER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19 EUROPE IVD CARDIAC DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20 EUROPE IVD IMMUNE SYSTEM DISORDER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 21 EUROPE IVD NEPHROLOGICAL DISEASES MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 22 EUROPE IVD GASTROINTESTINAL DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 23 EUROPE IVD OTHER INDICATION MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 24 EUROPE IVD MARKET, BY END USER, 2016-2023, ($MILLION)
TABLE 25 EUROPE IVD STANDALONE LABORATORIES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 26 EUROPE IVD HOSPITALS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27 EUROPE IVD ACADEMIC AND MEDICAL SCHOOLS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 28 EUROPE IVD POINT OF CARE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 29 EUROPE IVD OTHER END-USER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 30 EUROPE IVD MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 31 EUROPE IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 32 EUROPE IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 33 EUROPE IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34 EUROPE IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 35 GERMANY IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 36 GERMANY IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 37 GERMANY IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38 GERMANY IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 39 FRANCE IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 40 FRANCE IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 41 FRANCE IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 42 FRANCE IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 43 UK IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 44 UK IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 45 UK IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46 UK IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 47 CATEGORIZATION OF IVD DEVICES
TABLE 48 SPAIN IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 49 SPAIN IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 50 SPAIN IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 51 SPAIN IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 52 ITALY IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 53 ITALY IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 54 ITALY IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 55 ITALY IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 56 REST OF EUROPE IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 57 REST OF EUROPE IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 58 REST OF EUROPE IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 59 REST OF EUROPE IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 60 THERMO FISHER SCIENTIFIC INC. COMPANY SNAPSHOT
TABLE 61 ALERE INC. COMPANY SNAPSHOT
TABLE 62 BIOMERIEUX COMPANY SNAPSHOT
TABLE 63 DANAHER CORPORATION COMPANY SNAPSHOT
TABLE 64 ROCHE DIAGNOSTICS COMPANY SNAPSHOT
TABLE 65 BECTON DICKINSON AND COMPANY SNAPSHOT
TABLE 66 BIO-RAD LABORATORIES, INC. COMAPNY SNAPSHOT
TABLE 67 BAYER AG COMPANY SNAPSHOT
TABLE 68 SYSMEX CORPORATION COMPANY SNAPSHOT
TABLE 69 JOHNSON & JOHNSON PVT LTD. COMPANY SNAPSHOT

List of Figures

FIGURE 1 MARKET SEGMENTATION
FIGURE 2 TOP INVESTMENT POCKETS
FIGURE 3 TOP WINNING STRATEGIES, 2014-2016 (%)
FIGURE 4 TOP WINNING STRATEGIES: NATURE AND TYPE, 2014-2016
FIGURE 5 PORTERS FIVE FORCES ANALYSIS
FIGURE 6 MARKET SHARE ANALYSIS: IVD MARKET, 2016
FIGURE 7 EUROPE CHEMILUMINESCENCE IMMUNOASSAY (CLISA) MARKET, 2016-2023 ($MILLION)
FIGURE 8 EUROPE FLUORESCENCE IMMUNOASSAY (FIA) MARKET, 2016-2023 ($MILLION)
FIGURE 9 EUROPE COLORIMETRIC IMMUNOASSAY (CI) MARKET, 2016-2023 ($MILLION)
FIGURE 10 EUROPE RAPID TESTS MARKET, 2016-2023 ($MILLION)
FIGURE 11 EUROPE ENZYME-LINKED IMMUNOSPOT (ELISPOT) MARKET, 2016-2023 ($MILLION)
FIGURE 12 EUROPE RADIOIMMUNOASSAY (RIA) MARKET, 2016-2023 ($MILLION)
FIGURE 13 EUROPE WESTERN BLOT TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 14 EUROPE POLYMERIZE CHAIN REACTION PCR MARKET, 2016-2023 ($MILLION)
FIGURE 15 EUROPE ISOTHERMAL NUCLEIC ACID TECHNOLOGY (INAAT) MARKET, 2016-2023 ($MILLION)
FIGURE 16 EUROPE HYBRIDIZATION MARKET, 2016-2023 ($MILLION)
FIGURE 17 EUROPE DNA DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 18 EUROPE MICROARRAY MARKET, 2016-2023 ($MILLION)
FIGURE 19 EUROPE OTHER MOLECULAR DIAGNOSTIC TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 20 EUROPE BASIC METABOLIC PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 21 EUROPE LIVER PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 22 EUROPE RENAL PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 23 EUROPE LIPID PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 24 EUROPE THYROID FUNCTION PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 25 EUROPE ELECTROLYTE PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 26 EUROPE SPECIALITY CHEMICALS MARKET, 2016-2023 ($MILLION)
FIGURE 27 THERMO FISHER SCIENTIFIC INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 28 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 29 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 30 ALERE INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 31 ALERE INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 32 ALERE INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 33 BIOMERIEUX REVENUE: 2014-2016 ($MILLION)
FIGURE 34 BIOMERIEUX: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 35 BIOMERIEUX: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 36 DANAHER CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 37 DANAHER CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 38 DANAHER CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 39 ROCHE DIAGNOSTICS: REVENUE, 2014-2016 ($MILLION)
FIGURE 40 ROCHE DIAGNOSTICS: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 41 BECTON, DICKINSON AND COMPANY: REVENUE, 2014-2016 ($MILLION)
FIGURE 42 BECTON DICKINSON AND COMPANY: REVENUES BY SEGMENT (%) (2016)
FIGURE 43 BECTON DICKINSON AND COMPANY: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 44 BIO-RAD LABORATORIES: REVENUE, 2014-2016 ($MILLION)
FIGURE 45 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 46 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 47 BAYER AG: REVENUE, 2014-2016 ($MILLION)
FIGURE 48 BAYER AG: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 49 SYSMEX CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 50 SYSMEX CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 51 SYSMEX CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 52 JOHNSON & JOHSNON: REVENUE, 2014 - 2016 ($MILLION)
FIGURE 53 JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 54 JOHNSON & JOHNSON: REVENUE SHARE BY GEOGRAPHY, (%)(2016)